Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Capstone Therapeutics Corp (OTC: CAPS).

Full DD Report for CAPS

You must become a subscriber to view this report.


Recent News from (OTC: CAPS)

LipimetiX Development Announces Sub-License of Apo E Mimetic Peptide Platform to Anji Pharma, China
NATICK, Mass., May 07, 2018 (GLOBE NEWSWIRE) -- LipimetiX Development, Inc. (“LipimetiX” or “the Company”) announced today that Anji Pharmaceuticals, Inc. (“Anji Pharma”) has entered a licensing agreement for the LipimetiX platform of peptides (...
Source: GlobeNewswire
Date: May, 07 2018 09:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-07N/A0.0462N/AN/A10
2018-12-060.0460.04620.04620.046300
2018-12-050.050.0460.050.04625,121
2018-12-040.050.0460.050.04625,121
2018-12-030.0520.0460.0520.046166,750

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-0399,500166,75059.6702Short
2018-11-2835,00050,00070.0000Short
2018-11-012,8004,50062.2222Short
2018-10-292,5004,50055.5556Short
2018-10-181,5001,500100.0000Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CAPS.


About Capstone Therapeutics Corp (OTC: CAPS)

Logo for Capstone Therapeutics Corp (OTC: CAPS)

Capstone Therapeutics Corp. is a biotechnology company committed to developing a pipeline of novel therapeutic peptides aimed at helping patients with under served medical conditions.

 

 

 

Current Management

  • John M Holliman / CEO
  • Les Taeger / CFO
  • Barbara Dunford / Executive Assistant
  • John M Holliman / Chairman
  • Frederic J Feldman /
  • Elwood D Howse /
  • Matthew E. Lipman / Audit Committee Member
    • Mr. Lipman has served as a director of Mechanical Technology, Incorporated MKTY since October , . Since , Mr. Lipman has served as Managing Director of Brookstone Partners, a lower middle market private equity firm based in New York and an affiliate of BP Peptides, LLC. Mr. Lipman s responsibilities at Brookstone Partners include identifying and evaluating investment opportunities, performing transaction due diligence, managing the capital structure of portfolio companies and working with management teams to implement operational and growth strategies. In addition, Mr. Lipman is responsible for executing addon acquisitions and other portfolio companyrelated strategic projects. From July through June , Mr. Lipman was an analyst in the mergers and acquisitions group at UBS Financial Services Inc. responsible for formulating and executing on complex merger, acquisition and financing strategies for Fortune companies in the industrial, consumer products and healthcare sectors. Mr. Lipman currently serves on the Board of Directors of Instone, LLC and Denison Pharmaceuticals, LLC. Mr. Lipman has a B.S. in Business Administration from Babson College. Mr. Lipman brings over years of experience working with companies to establish growth strategies and execute acquisitions, is proficient in reading and understanding financial statements, generally accepted accounting principles and internal controls as a direct result of his investment experience evaluating companies for potential investments, the management of financial reporting and capital structure for three portfolio companies, as well as relevant experience in board service, which the Board believes qualifies him to serve as a director. In addition, his experience working with the Chief Financial Officers of portfolio companies to manage and analyze businesses and manage the capital structure of operating companies makes him well qualified for his service on the Audit Committee.
  • Michael M. Toporek / Compensation Committee Member
    • Mr. Toporek has served as a director of Mechanical Technology, Incorporated MKTY since October , . Since , Mr. Toporek has served as the Managing General Partner of Brookstone Partners, a lower middle market private equity firm based in New York and an affiliate of BP Peptides, LLC. Prior to founding Brookstone Partners in , Mr. Toporek was both an active principal investor and an investment banker. Mr. Toporek began his career in Chemical Bank s Investment Banking Group, later joined Dillon, Read and Co., which became UBS Warburg Securities Ltd. during his tenure, and SG Cowen and Company. Mr. Toporek currently serves on the Board of Trustees of Harlem Academy. Mr. Toporek has a B.A. in Economics and an M.B.A from the University of Chicago. Mr. Toporek brings strategic and financial expertise to the Board as a result of his experience with Brookstone Partners, which the Board believes qualifies him to serve as a director.

Current Share Structure

  • Market Cap: $2,447,343 - 03/16/2018
  • Authorized: 150,000,000 - 03/15/2018
  • Issue and Outstanding: 54,385,411 - 03/15/2018

 


Recent Filings from (OTC: CAPS)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 11 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 07 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: February, 28 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 01 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: February, 01 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: January, 23 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: November, 13 2017
Amendment to a previously filed 10-K
Filing Type: 10-K/AFiling Source: edgar
Filing Date: October, 30 2017

 

 


Daily Technical Chart for (OTC: CAPS)

Daily Technical Chart for (OTC: CAPS)


Stay tuned for daily updates and more on (OTC: CAPS)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: CAPS)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CAPS is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of CAPS and does not buy, sell, or trade any shares of CAPS. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/